Medtronic

Medtronic

Develops and manufactures medical devices and therapies

About Medtronic

Simplify's Rating
Why Medtronic is rated
A-
Rated A on Competitive Edge
Rated A on Growth Potential
Rated B on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

10,001+

Company Stage

IPO

Total Funding

$3.2M

Headquarters

Fridley, Minnesota

Founded

1949

Overview

Medtronic provides medical technology, services, and solutions to improve patient care. The company develops a variety of medical devices, such as pacemakers, insulin pumps, surgical tools, and neurostimulation devices, which help diagnose, prevent, and treat chronic diseases. These products are used by hospitals and healthcare professionals around the world. Medtronic stands out from competitors by not only focusing on product development but also offering training, patient management programs, and technical support to healthcare providers. The goal of Medtronic is to enhance patient outcomes and lower healthcare costs through comprehensive solutions.

đź’µ
Funded Recently
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased AI adoption in medical imaging boosts Medtronic's diagnostic device efficiency.
  • Telehealth growth expands opportunities for Medtronic's connected devices and solutions.
  • Personalized medicine trends drive demand for Medtronic's adaptive technologies like BrainSense™ aDBS.

What critics are saying

  • Stricter European regulations may delay Medtronic's product launches.
  • Rising competition in diabetes care from Dexcom and Abbott threatens market share.
  • Supply chain issues, especially in semiconductors, could disrupt Medtronic's device production.

What makes Medtronic unique

  • Medtronic's BrainSense™ aDBS offers personalized Parkinson's treatment, enhancing patient outcomes.
  • The company leads in minimally invasive surgical tools, meeting growing market demand.
  • Medtronic's global presence in over 150 countries strengthens its market reach and influence.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$3.2M

Above

Industry Average

Funded Over

3 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Debt Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Employee Assistance Program

Wellness Program

Company News

PR Newswire
Feb 18th, 2025
Medtronic Reports Third Quarter Fiscal 2025 Financial Results

Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and NeuromodulationGALWAY, Ireland, Feb. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025.Key Highlights

Surgical Robotics Technology
Feb 13th, 2025
Medtronic Acquires Certain Nano Surface Technology from Nanovis

Medtronic acquires certain nano surface technology from Nanovis.

Retia Medical
Feb 11th, 2025
Retia signs US distribution Agreement for Argos(R) Cardiac Output Monitor with Medtronic

WHITE PLAINS, NEW YORK, UNITED STATES, Febryary 11, 2025 - Retia Medical, an innovator in AI algorithms for patient monitoring and management, announced that it has entered into an agreement with Medtronic plc, a global leader in healthcare technology, to distribute the Argos Cardiac Output Monitor designed to provide healthcare professionals with highly accurate hemodynamic data to support the treatment of high-risk surgical and critically ill patients.

PR Newswire
Feb 5th, 2025
Medtronic To Announce Financial Results For Its Third Quarter Of Fiscal Year 2025

GALWAY, Ireland, Feb. 5, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of fiscal year 2025 on Tuesday, February 18, 2025. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's third quarter of fiscal year 2025, which ended on Friday, January 24, 2025. Medtronic will host a video webcast at 7:00 a.m

Stock Titan
Jan 21st, 2025
Medtronic appoints Thierry Piéton as Chief Financial Officer

GALWAY, Ireland, Jan. 21, 2025 /PRNewswire/ - Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Thierry Piéton has been appointed Chief Financial Officer for the company, effective March 3, 2025.

Recently Posted Jobs

Sign up to get curated job recommendations

Medtronic is Hiring for 0 Jobs on Simplify!

Find jobs on Simplify and start your career today

đź’ˇ
We update Medtronic's jobs every 8 hours, so check again soon! Browse all jobs →